We are live on ! Find out more
AEON icon

AEON Biopharma
AEON

73 hedge funds and large institutions have $192M invested in AEON Biopharma in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 4

133% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 6

24% more funds holding

Funds holding: 59 → 73 (+14)

12% more capital invested

Capital invested by funds: $172M → $192M (+$20.2M)

0.2% more ownership

Funds ownership: 0.79% → 0.99% (+0.2%)

Holders
73
Holders Change
+14
Holders Change %
+23.73%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
14
Reduced
6
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
+$6.57M
2
KIM
Karpus Investment Management
New York
+$4.51M
3
Millennium Management
Millennium Management
New York
+$3.74M
4
JP Morgan Chase
JP Morgan Chase
New York
+$2.67M
5
PC
Periscope Capital
Ontario, Canada
+$2.5M

Top Sellers

Rank Fund Capital Flow
1
PAMP
Polar Asset Management Partners
Ontario, Canada
-$2.92M
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$2.44M
3
WAM
Wolverine Asset Management
Illinois
-$1.72M
4
SC
Sculptor Capital
New York
-$1.46M
5
CL
CSS LLC
Illinois
-$1.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
State of Wisconsin Investment Board
26
State of Wisconsin Investment Board
Wisconsin
$2.43M +$879K +1,250 +56%
ACA
27
Arena Capital Advisors
California
$2.43M – – –
MP
28
Mangrove Partners
Connecticut
$2.06M -$768K -1,092 -27%
D.E. Shaw & Co
29
D.E. Shaw & Co
New York
$2M +$872K +1,240 +77%
CL
30
CSS LLC
Illinois
$1.98M -$1.28M -1,825 -39%
Balyasny Asset Management
31
Balyasny Asset Management
Illinois
$1.94M – – –
DCM
32
Dupont Capital Management
Delaware
$1.46M – – –
FCM
33
Farallon Capital Management
California
$1.46M – – –
FIG
34
Fortress Investment Group
New York
$1.46M – – –
AR
35
Advisory Research
Illinois
$1.44M +$28.1K +40 +2%
AA
36
AQR Arbitrage
Connecticut
$1.22M -$271K -385 -18%
CC
37
Covalis Capital
United Kingdom
$1.22M – – –
LOAMU
38
Lombard Odier Asset Management (USA)
New York
$1.21M +$1.22M +1,736 New
MCM
39
Moore Capital Management
New York
$973K – – –
CCFM
40
Cohen & Co Financial Management
New York
$971K +$977K +1,389 New
AC
41
Athos Capital
Hong Kong
$867K – – –
SCM
42
Saba Capital Management
New York
$845K – – –
SSA
43
Schonfeld Strategic Advisors
New York
$833K +$837K +1,191 New
CF
44
Cantor Fitzgerald
New York
$779K +$783K +1,114 New
EH
45
EMG Holdings
Connecticut
$729K +$733K +1,042 New
QGA
46
Q Global Advisors
Texas
$713K +$717K +1,020 New
KCM
47
Kawa Capital Management
Florida
$679K +$683K +972 New
HighTower Advisors
48
HighTower Advisors
Illinois
$653K – – –
HF
49
HRT Financial
New York
$495K +$498K +708 New
SCM
50
Segantii Capital Management
Hong Kong
$487K – – –
1
2
3 4

AEON Hedge Fund Activity: Q4 2021 in Review

73 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q4 2021, worth a combined $192M — up 12% from $172M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new AEON positions and 4 closed out — a net gain of 14 holders — while 14 added to existing stakes and 6 trimmed.

The largest buyer was Marshall Wace, adding an estimated $6.57M. The largest seller was Polar Asset Management Partners, exiting entirely with an estimated $2.92M sold.

  • 73 institutional investors held AEON Biopharma (AEON) as of Q4 2021, up from 59 in Q3 2021.
  • Funds reported $192M of AEON Biopharma stock for Q4 2021, up 12% quarter-over-quarter.
  • 18 funds opened new AEON Biopharma positions in Q4 2021 and 4 closed out, a net change of +14 holders.
  • The largest AEON Biopharma buyer in Q4 2021 was Marshall Wace, an estimated $6.57M added.
  • The largest AEON Biopharma seller in Q4 2021 was Polar Asset Management Partners, an estimated $2.92M sold.

Based on aggregated 13F filings for Q4 2021.